ENDYMED Merges with Majority Shareholder Shanghai Haohai Biological Technology

EmergentMedTech Merges with TRU Biologix

January 22, 2025

Biotechnology

EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.

Baird Medical and ExcelFin Acquisition Corp Complete Business Combination

October 1, 2024

Medical Devices

Baird Medical Investment Holdings Limited, a Guangzhou-based developer and manufacturer of microwave ablation medical devices, has completed its business combination with ExcelFin Acquisition Corp., a Nasdaq-listed SPAC. The combined public company (PubCo) will trade on Nasdaq under the ticker BDMD; founders and co-sponsor Grand Fortune Capital subscribed to a $4.9 million convertible preferred investment in the company.

INVO Bioscience Acquires NAYA Biosciences; Combined Company to Operate as NAYA Biosciences

October 14, 2024

Biotechnology

INVO Bioscience has completed a reverse-triangular merger to acquire 100% of NAYA Biosciences, and the combined company will operate as NAYA Biosciences (NASDAQ: NAYA). The combined business will continue INVO's revenue-generating fertility operations while adding NAYA's clinical-stage oncology and autoimmune therapeutics pipeline and updating management and board composition.

Montagu Acquires Majority Stake in HTL Biotechnology

February 28, 2022

Pharmaceuticals

Montagu, a leading private equity firm, has acquired a majority stake in HTL (HTL Biotechnology) from Bridgepoint, with minority shareholders Naxicap and Téthys Invest retaining their holdings. Montagu will support HTL's international expansion, R&D and premium product positioning and has appointed Paul Navarre as Chairman to help drive the company's next growth phase.

ARCHIMED Acquires Majority Stake in Xpress Biologics

October 5, 2021

Biotechnology

ARCHIMED has acquired a majority stake in Liège-based Xpress Biologics and will finance a ten-fold expansion of the company's plasmid DNA production capacity with the implementation of GMP services. Founders Christian Rodriguez, Philippe Ledent and Marc Daukandt, together with public investor Noshaq, will reinvest proceeds; ARCHIMED is investing via its MED II fund to help internationalize distribution into the US and Asia‑Pacific.

Kemin Industries Acquires CJ Youtell Biotech

September 23, 2025

Biotechnology

Kemin Industries has acquired CJ Youtell Biotech, the enzymes and fermentation subsidiary of CJ Bio, gaining full ownership of CJ Youtell’s fermentation plants and enzyme product portfolio. The acquisition adds fermentation capacity in Shandong and Hunan, China and expands Kemin’s global enzyme R&D, manufacturing and product offerings across animal feed, food, aquaculture and industrial end markets.